Cell Therapy Catapult Launches New CAR-T Company Targeting Solid Tumors
This article was originally published in Scrip
Executive Summary
The Cell Therapy Catapult (CTC), a UK-based organization focused on growth of the UK cell and gene therapy sector, is teaming up with the University of Birmingham and Cancer Research UK to develop a new generation chimeric antigen receptor T-Cell (CAR-T) immune-oncology therapy for solid tumors.